This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal cancer
Sign written informed consent before implementing any experimental procedures
Over 18 years old
Histologically confirmed as colorectal adenocarcinoma without liver metastasis
At least one measurable lesion (RECIST 1.1)
Known presence of active central nervous system (CNS) metastases and/or cancerous meningitis
Microsatellite instability (MSI-H) or loss of expression of DNA mismatch repair genes (dMMR)
Currently participating in interventional clinical research treatment, or having received other research drugs or used research instruments for treatment within 4 weeks before the first administration
Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs that stimulate or synergistically inhibit T cell receptors